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Abstract
Background: TNF inhibitors have been used as a treatment for moderate to severe RA patients. However, reliable
biomarkers that predict therapeutic response to TNF inhibitors are lacking. In this study, we investigated whether
chemokines may represent useful biomarkers to predict the response to TNF inhibitor therapy in RA.
Methods: RA patients (n = 29) who were initiating adalimumab or etanercept were recruited from the rheumatology
clinics at Cooper University Hospital. RA patients were evaluated at baseline and 14 weeks after TNF inhibitor therapy,
and serum levels of CXCL10, CXCL13, and CCL20 were measured by ELISA. Responders (n = 16) were defined
as patients who had good or moderate response at week 14 by EULAR response criteria, and nonresponders
(n = 13) were defined as having no response.
Results: Responders had higher levels of baseline CXCL10 and CXCL13 compared to nonresponders (p = 0.03
and 0.002 respectively). There was no difference in CCL20 levels. CXCL10 and CXCL13 were highly correlated
with each other, and were higher in seropositive RA patients. CXCL10 and CXCL13 levels were decreased after
TNF inhibitor therapy in responders. Baseline additive levels of CXCL10 + 13 were correlated with changes in
DAS score at 14 weeks after TNF inhibitor therapy (r = 0.42, p = 0.03), and ROC curve analyses for predictive
ability of CXCL10 + 13 showed an AUC of 0.83.
Conclusions: Elevated baseline levels of CXCL10 and CXCL13 were associated with favorable response to TNF
inhibitor therapy in RA. Subjects with high CXCL10 and high CXCL13 may represent a subset of RA patients
whose inflammatory reactions are primarily driven by TNF.
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Background
Rheumatoid arthritis (RA) is a disease that is charac-
terized by synovial inflammation, cartilage and bone
destruction, and systemic features [1, 2]. Advances in
understanding the pathogenesis of the disease have
fostered the development of new therapeutics. Tumor
necrosis factor (TNF) inhibitors are used as a treatment
for moderate to severe RA patients who have inad-
equate responses to conventional disease-modifying an-
tirheumatic drugs (DMARDs) including methotrexate.
However, reliable predictive biomarkers of therapeutic
response for TNF inhibitor therapy are lacking [3].
Several studies have been conducted to discover pre-
dictive biomarkers for RA therapies. It has been reported
that type I interferon (IFN) signature is associated with
the therapeutic response to TNF inhibitors and rituximab
[4–7]. C-X-C motif chemokine 10 (CXCL10) is induced
by type I and II IFNs [8, 9]. Recruitment and activation of
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C-X-C chemokine receptor type 3 (CXCR3)-positive T
helper 1 (Th1) lymphocytes and monocytes by CXCL10
may lead to TNF production in RA [10, 11]. In other
studies, C-X-C motif chemokine 13 (CXCL13) has been
reported to be a predictive biomarker for RA therapies
[12, 13]. CXCL13, a chemokine that attracts B lympho-
cytes and follicular helper T lymphocytes (TFH) by bind-
ing to C-X-C chemokine receptor type 5 (CXCR5), is
upregulated in a subset of T cells by TNF or interleukin 6
(IL-6) in RA [14, 15] as well as in follicular dendritic cells
in the germinal center of lymphoid tissues [16]. Lastly,
baseline interleukin 17 (IL-17) levels are inversely corre-
lated with response to TNF inhibitor therapy in RA [17].
C-C motif chemokine 20 (CCL20) attracts T helper 17
(Th17) lymphocytes expressing C-C chemokine receptor
type 6 (CCR6), and induced by interleukin 1β (IL-1β),
IL-17, and TNF [18, 19].
In this study, we investigated whether these three
chemokines may represent useful predictive biomarkers
for TNF inhibitor therapy in RA patients. We measured
CXCL10, CXCL13, and CCL20 in RA patients who were
initiating TNF inhibitor therapy and correlated each
chemokine level with the therapeutic response.
Methods
Patients and assessment
Patients with RA who met the inclusion and exclusion
criteria were recruited during routine care in the rheuma-
tology clinics at the Cooper University Hospital (Camden,
NJ, USA). The inclusion criteria for this study were:
(1) diagnosis of RA by American College of Rheuma-
tology (ACR) criteria; (2) active RA defined by disease
activity score (DAS) >4.4; (3) inadequate response to
methotrexate; (4) clinical indication for initiating adalimu-
mab or etanercept treatment. The exclusion criteria were:
(1) diagnosis of other connective tissue diseases including
systemic lupus erythematosus, systemic sclerosis, or derm-
atomyositis, or interstitial lung disease; (2) diagnosis of
chronic infection including viral hepatitis or human
immunodeficiency virus; (3) history of malignancy. All
29 patients except one were continued on baseline
methotrexate and other DMARDs while taking adali-
mumab (22 patients) or etanercept (7 patients). The pa-
tients were assessed and peripheral blood samples were
obtained at baseline and 14 weeks after TNF inhibitor
therapy. The results of rheumatoid factor (RF), anti-
cyclic citrullinated peptide antibody (anti-CCP), and
erythrocyte sedimentation rate (ESR) tests were ob-
tained as part of patient care. Responders were defined
as patients who had good to moderate response at week
14 by European League Against Rheumatism (EULAR)
response criteria (14 with adalimumab and 2 with eta-
nercept treatment), and nonresponders were defined as
having no response (8 with adalimumab and 5 with
etanercept treatment). The research protocol was ap-
proved by the Institutional Review Board of Cooper
University Hospital and all patients provided written in-
formed consent for participation in the study.
Measurement of chemokine levels
Freshly isolated serum samples were aliquoted and stored
in a −80 °C freezer until use. Commercial enzyme-linked
immunosorbent assay (ELISA) kits were used for serum
measurements of CXCL10 (R&D, Minneapolis, MN, USA),
CXCL13 (Sigma-Aldrich, St Louis, MO, USA), and CCL20
(Sigma-Aldrich, St Louis, MO, USA).
Statistical analyses
Statistical analyses were performed using SAS v9.4 (SAS
Institute, Cary, NC, USA), and graphs were generated
using GraphPad Prism 6.0 (GraphPad Software, La Jolla,
CA, USA). Continuous variables were compared using
Wilcoxon ranked sum test, and dichotomous variables
were compared using Fisher’s exact test. Correlations
between pairs of continuous variables were performed
using Spearman correlation coefficient. Differences be-
tween pretreatment and posttreatment chemokine levels
were compared using analysis of variance (ANOVA)
for repeated measures. Receiver operating characteris-
tic (ROC) curve analysis was performed to assess the
predictive ability of cytokine variables. In all the tests,
a two-sided p value <0.05 was considered significant.
Results
Baseline serum CXCL10 and CXCL13 levels are higher in
responders to TNF inhibitor therapy
Twenty-nine RA patients who were about to start either
adalimumab or etanercept after having an inadequate
response to methotrexate and other DMARDs were
recruited. Five patients had been treated with a TNF
inhibitor previously, and their last treatment was at least
3 months ago. After 14 weeks of TNF inhibitor therapy,
using EULAR response criteria, the patients were classi-
fied into 16 good and moderate responders (collectively
termed hereafter as ‘responders’) and 13 nonresponders.
Their baseline characteristics, summarized in Table 1,
showed no significant differences between responders
and nonresponders.
Baseline chemokine levels were measured by ELISA be-
fore starting TNF inhibitor therapy and compared between
responders and nonresponders (Fig. 1a). Responders had
significantly higher serum levels of CXCL10 (606 ± 581
vs 283 ± 265 pg/ml, p = 0.03) and CXCL13 (383 ± 644 vs
27 ± 24 pg/ml, p = 0.002) compared to nonresponders.
There was no difference in CCL20 levels between re-
sponders and nonresponders (14 ± 13 vs 19 ± 31 pg/ml,
p = 0.78).
Han et al. Arthritis Research & Therapy  (2016) 18:93 Page 2 of 7
Among patients who were treated with adalimumab
(n = 22), baseline CXCL10 and CXCL13 levels were higher
in responders than in nonresponders (p = 0.02 and p =
0.04 respectively). Among patients who were treated with
etanercept (n = 7), CXCL13 levels were higher in re-
sponders (p = 0.045), and CXCL10 levels were numerically
higher in responders, but the difference did not reach
statistical significance (p = 0.20).
CXCL10 and CXCL13 levels are correlated with each other
and are higher in seropositive RA patients
The relationship between chemokine levels and disease
activity was assessed. Baseline or posttreatment levels of
CXCL10, CXCL13, or CCL20 were not correlated with
DAS28 or ESR (data not shown). Of note, baseline and
posttreatment levels of CXCL10 and CXCL13 were
correlated with each other (r = 0.72, p = 0.00001 and
r = 0.59, p = 0.001 respectively) (Fig. 1b).
Chemokine levels were compared between seropositive
and seronegative patients. Baseline CXCL10 and CXCL13
levels were higher in anti-CCP-positive patients than in
anti-CCP-negative patients (p = 0.02 and p = 0.005 re-
spectively). Only baseline CXCL13 levels were higher in
RF-positive patients than in RF-negative patients (p =
0.02) (Table 2). There were no significant differences in
posttreatment CXCL10 and CXCL13 levels between RF-
positive and RF-negative patients (p = 0.57 and p = 0.72
respectively), and anti-CCP-positive and anti-CCP-negative
patients (p = 0.09 and p = 0.21 respectively).
CXCL10 and CXCL13 levels decrease after TNF inhibitor
therapy in responders
Posttreatment chemokine levels at 14 weeks after TNF
inhibitor therapy were measured and compared to pre-
treatment (baseline) levels (Table 3). In responders,
CXCL10, CXCL13, and CCL20 levels were decreased
after TNF inhibitor therapy (p = 0.01, p = 0.0001, and
p = 0.003 respectively). In nonresponders, CXCL13 levels
did not change (p = 0.86) and CXCL10 and CCL20 levels
were decreased (p = 0.04 and p = 0.047 respectively). The
percentage change was compared between responders and
nonresponders. CXCL13 levels were decreased by 62 % of
baseline levels after TNF inhibitor therapy in responders,
and increased by 6 % in nonresponders (p = 0.08). There
was no difference in the percentage change of CXCL10
and CCL20 between responders and nonresponders.
Baseline CXCL10 and CXCL13 levels predict response to
TNF inhibitor therapy
RA patients were then classified into four groups (high
CXCL10/high CXCL13, high CXCL10/low CXCL13, low
Fig. 1 a Baseline serum chemokine levels in responders (n = 16) and nonresponders (n = 13) to TNF inhibitor therapy. CXCL10 (p = 0.03)
and CXCL13 (p = 0.002) levels were higher in responders than in nonresponders. The chemokine levels in the two groups were compared
using Wilcoxon ranked sum test. Bars represent mean ± standard deviation. R responders, NR nonresponders. b Correlation between
baseline CXCL10 and CXCL13 levels. Baseline CXCL10 and CXCL13 levels were highly correlated (r = 0.72, p = 0.00001). The association
between the two chemokine levels was assessed using Spearman correlation






Age (years) 51.6 ± 12.7 50.7 ± 8.1 0.80a
Gender (female %) 69 (11/16) 77 (10/13) 0.70b
Duration (years) 6.5 ± 4.9 7.4 ± 7.5 0.66a
RF or anti-CCP positive (%) 75 (12/16) 54 (7/13) 0.27b
DAS28 ESR 6.2 ± 1.1 6.7 ± 0.6 0.15a
ESR (mm) 37 ± 31 30 ± 22 0.79a
Values are presented as mean with standard deviation. P values were
determined by Wilcoxon ranked sum testa and by Fisher’s exact testb
RF rheumatoid factor, anti-CCP anti-cyclic citrullinated peptide, DAS28 ESR dis-
ease activity score in 28 joints based on erythrocyte sedimentation rate,
ESR erythrocyte sedimentation rate
Han et al. Arthritis Research & Therapy  (2016) 18:93 Page 3 of 7
CXCL10/highCXCL13, low CXCL10/low CXCL13) based
on baseline CXCL10 and CXCL13 cutoffs defined by their
median values (260 pg/ml and 50 pg/ml respectively), and
their response to TNF inhibitor therapy was compared.
Ten out of 12 patients in the high CXCL10/high CXCL13
group were responders, and nine out of 12 patients in the
low CXCL10/low CXCL13 group were nonresponders.
A chemokine score, CXCL10 + 13, was created by sim-
ply adding baseline CXCL10 and CXCL13 levels. There
was a significant difference in baseline CXCL10 + 13
between responders and nonresponders (988 ± 1050 vs
310 ± 283 pg/ml, p = 0.006). Baseline CXCL10 + 13 and
CXCL13 were correlated with changes in DAS28 at
14 weeks after TNF inhibitor therapy (r = 0.42, p = 0.03
and r = 0.54, p = 0.003 respectively), and CXCL10 levels
were not correlated (r = 0.25, p = 0.20) (Fig. 2a). ROC
curve analysis was performed to assess the predictive
ability of CXCL10 + 13 for EULAR good or moderate
response to TNF inhibitor therapy. CXCL10 + 13 showed
significant predictive ability based on the area under the
curve (AUC) of 0.83 (Fig. 2b).
Discussion
This study demonstrates that baseline CXCL10 and
CXCL13 levels are associated with favorable response to
TNF inhibitor therapy in moderate to severe RA pa-
tients. On the other hand, CCL20 levels were relatively
low in RA patients and there was no difference between
responders and nonresponders. When analyzed separ-
ately based on the TNF inhibitors patients received, the
results were similar, except that the difference for CXCL10
in patients treated with etanercept was not statistically sig-
nificant, presumably due to the low subject number in this
group. All the patients included in this study had inad-
equate response to methotrexate and had high disease
activity measured by DAS28 when starting TNF inhibitor
therapy.
CXCL10 is induced by type I and II IFNs [8, 9] as well
as TNF [20], and has been evaluated as a surrogate
biomarker to reflect the IFN signature upregulated in
autoimmune rheumatic diseases including RA and sys-
temic lupus erythematosus (SLE) [21, 22]. A previous
study has shown that infliximab therapy leads to signifi-
cant decrease in serum CXCL10 levels in RA patients
[23], which is consistent with our study’s findings. Of
note, RA patients with high baseline type I IFN activity
have a good response to TNF inhibitors [4]. Addition-
ally, it has been reported that type I IFN signature is
induced by TNF in RA patients [24].
CXCR3-expressing Th1 lymphocytes and monocytes
recruited by CXCL10 secrete TNF in RA [10, 11]. Fur-
thermore, TNF induces type I IFN synthesis by macro-
phages and fibroblast-like synoviocytes, which in turn
stimulates CXCL10 secretion in an autocrine manner
and creates a positive feedback loop [25, 26]. In this
regard, CXCL10 may be used as a marker associated
with both TNF and type I IFN pathways, which are
closely linked to each other in RA. This study provided
additional evidence in support of the above notion.
CXCL13 is constitutively expressed by follicular den-
dritic cells and is involved in formation of secondary
lymphoid tissues in RA [16]. Additionally, it is upregu-
lated in a subset of T cells by T cell receptor engagement
and by TNF or IL-6 [14, 15] as well as in macrophages
[27]. CXCL13 is implicated in germinal center formation
by B lymphocytes and follicular helper T lymphocytes
(TFH), and likely in their recruitment into the inflamed
synovial tissues in RA, where they may contribute to
pathogenesis by generating local immune responses and
antibody production. Immunoglobulin G (IgG)-containing
Table 2 Baseline chemokine levels in seropositive and
seronegative RA patients. Values are presented as mean with
standard deviation. P values were determined by Wilcoxon
ranked sum test
IgM RF+ (n = 16) IgM RF- (n = 13) p value
CXCL10 (pg/ml) 510.2 ± 465.2 400.4 ± 525.3 0.16
CXCL13 (pg/ml) 371.6 ± 649.0 40.3 ± 55.6 0.02*
CCL20 (pg/ml) 9.7 ± 10.3 23.8 ± 30.5 0.09
Anti-CCP+ (n = 15) Anti-CCP- (n = 14) p value
CXCL10 (pg/ml) 557.3 ± 458.0 357.8 ± 512.9 0.02*
CXCL13 (pg/ml) 396.6 ± 663.8 37.2 ± 54.4 0.005*
CCL20 (pg/ml) 9.6 ± 9.9 22.9 ± 29.7 0.12
IgG immunoglobulin G, RF rheumatoid factor, CXCL10 C-X-C motif chemokine
10, CXCL13 C-X-C motif chemokine 13, CCL20 C-C motif chemokine 20,
anti-CCP anti-cyclic citrullinated peptide
*p < 0.05
Table 3 Pretreatment (baseline) and posttreatment chemokine
levels in responders and nonresponders. P values were
determined by analysis of variance (ANOVA) for repeated
measures
Responders Nonresponders
mean ± SD p value mean ± SD p value
CXCL10 (pg/ml)
Pretreatment 605.5 ± 580.6 0.01* 283.2 ± 265.1 0.04*
Posttreatment 411.1 ± 458.3 218.4 ± 237.3
CXCL13 (pg/ml)
Pretreatment 382.7 ± 644.3 <0.0001* 26.7 ± 23.8 0.86
Posttreatment 90.6 ± 128.2 35.7 ± 46.8
CCL20 (pg/ml)
Pretreatment 13.6 ± 12.7 0.003* 19.0 ± 31.0 0.047*
Posttreatment 6.9 ± 8.9 7.2 ± 7.2
CXCL10 C-X-C motif chemokine 10, CXCL13 C-X-C motif chemokine 13,
CCL20 C-C motif chemokine 20
*p < 0.05
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immune complexes stimulate TNF production by mono-
cytes via direct activation of Fc gamma receptor III
(FcγRIII) [28]. It has been reported that CXCL13 was
higher in seropositive RA patients than in seronegative
RA patients [29, 30], and our study’s findings are consist-
ent with these reports. CXCL13 is associated with severe
RA with persistent ultrasonographic synovitis despite non-
biologic DMARDs therapy [31].
There have been two inconsistent reports on the roles
of CXCL13 as a predictive marker for the response to
TNF inhibitor in RA patients [12, 13]. In the first study,
baseline CXCL13 levels in early RA patients were in-
versely correlated with disease activity at 12 months
after DMARDs and adalimumab therapy [12], which is
consistent with the findings of our study. In the second
study, CXCL13 was associated with lower ACR50 re-
sponse rate to adalimumab and higher ACR50 response
rate to tocilizumab, an IL-6 receptor inhibitor, after
24 weeks of therapy [13]. The study was a post hoc
analysis of ADalimumab ACTemrA (ADACTA) trial
results where tocilizumab monotherapy and adalimu-
mab monotherapy were compared [32]. ROC analysis
in that study has shown CXCL13 has only modest pre-
dictive ability with an AUC of 0.6 [13]. As opposed to
the ADACTA trial, all but one patient in our study
were continued on baseline methotrexate and other
DMARDs while taking TNF inhibitor. Furthermore,
baseline CXCL13 and CXCL10 levels were highly corre-
lated with each other in our study, and CXCL13 levels
decreased after TNF inhibitor therapy only in responders.
However, since CXCL13 was found to be a predictive
biomarker for the response to tocilizumab [13], it would
not be clinically helpful in choosing between TNF inhibi-
tors and tocilizumab.
Response of RA patients to TNF inhibitor therapy could
be associated with quality (i.e., subset) or quantity (i.e.,
severity) of synovial inflammation. CXCL10 and CXCL13
levels were not associated with disease activity in this
study, and the present data are in favor of a qualitative
rather than quantitative association between baseline
CXCL10 and CXCL13 levels and the therapeutic re-
sponse to TNF inhibitors. Therefore, we hypothesize
that patients with high CXCL10 and high CXCL13
define a subset of RA whose inflammatory reactions are
primarily driven by TNF and thus respond to TNF
inhibitor therapy. The potential mechanistic interac-
tions between CXCL10 and CXCL13 in RA remain to
be determined in further studies. Additionally, it has
been reported that C-C motif chemokine 19 (CCL19)
predicts the clinical response to rituximab in RA [33],
and we plan to further investigate this finding in future
studies.
This study has several limitations. First, the study popu-
lation is from a single tertiary care center and the results
need to be confirmed in a larger population. There is
furthermore a possibility that the data may have been
biased by confounders, which may be better controlled in
future studies by stricter inclusion and exclusion criteria
and a study protocol. On the other hand, these data reflect
findings from a real clinical practice setting. Another
limitation is that this study did not include a control
group of healthy individuals. Serum levels of CXCL10 and
CXCL13 in RA patients are significantly higher than in
healthy controls [34], and future studies will be needed to
Fig. 2 a Correlations between baseline CXCL10 + 13, CXCL10, CXCL13 and change in DAS28 at 14 weeks after TNF inhibitor therapy. Baseline
CXCL10 + 13 (r = 0.42, p = 0.03) and CXCL13 (r = 0.54, p = 0.003) were correlated with change in DAS28 at 14 weeks. The associations between
chemokine levels and change in DAS28 were assessed using Spearman correlation. b Predictive ability of CXCL10 + 13 for the response to TNF
inhibitor therapy at 14 weeks. Area under the curve (AUC) in ROC curve analysis is 0.83
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assess whether chemokine levels in the subsets of RA
patients based on the clinical response to TNF inhibitor
therapy are higher than the normal range. While some RA
patients may take longer than 14 weeks to respond to
TNF inhibitor therapy, many nonresponders in this study
switched to a different agent after 14 weeks, preventing us
from assessing later clinical responses.
Conclusions
In conclusion, our results show that serum levels of
CXCL10 and CXCL13 may be valuable predictive bio-
markers of response to TNF inhibitor therapy. The
decrease of CXCL10 and CXCL13 after treatment in
responders is consistent with their biological significance
in the disease process. Importantly, CXCL10 and CXCL13
levels are not correlated with disease activity or severity,
but rather appear to be markers for a subset of RA pa-
tients whose inflammatory reactions are driven by TNF.
Replication of these results in larger, controlled cohorts
will be necessary to confirm their significance.
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